Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) generated frequent news as a biopharmaceutical company focused on developing new solid tumor cancer therapies and as the vehicle for a significant reverse merger with TuHURA Biosciences, Inc. Company press releases describe Kintara as located in San Diego, California and dedicated to novel cancer therapies for patients with unmet medical needs, with a lead program centered on REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
The KTRA news flow prominently features updates on REM-001 Therapy, including details of an open-label CMBC study, prior Phase 2/3 clinical experience, and the role of a Small Business Innovation Research grant from the National Institutes of Health in supporting study costs. These items provide context on the company’s proprietary late-stage photodynamic therapy platform, which combines a laser light source, a light delivery device, and the REM-001 drug product.
Another major theme in Kintara’s news coverage is its merger with TuHURA Biosciences, Inc. Articles outline the definitive merger agreement, stockholder meetings, voting instructions, and the strategic rationale for combining Kintara’s oncology assets with TuHURA’s Phase 3 registration-stage immuno-oncology programs. Releases discuss the expected ownership structure of the combined company, the planned corporate name change to TuHURA Biosciences, Inc., and the transition of trading to the Nasdaq Capital Market under the symbol HURA.
News items also detail corporate actions tied to the merger, including the approval and implementation of a 1-for-35 reverse stock split and the establishment of Contingent Value Rights (CVRs) to provide potential additional share consideration to Kintara stockholders upon achievement of specified REM-001 study milestones. Additional coverage includes reminders to stockholders to vote on key proposals, adjournments and reconvening of special meetings, and fiscal year financial results accompanied by corporate updates.
For readers following KTRA historically, this news archive offers insight into Kintara’s oncology development efforts, its financial and strategic decisions, and the sequence of events that led to the transformation of the Kintara listing into TuHURA Biosciences, Inc. under the HURA ticker. Regular review of these releases helps clarify how the company’s clinical programs and corporate structure evolved over time.
TuHURA Biosciences has entered into an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of the anti-VISTA antibody KVA12123 and related assets. KVA12123 targets VISTA, a checkpoint on quiescent T-cells, to reverse immune suppression and remodel the tumor microenvironment. This inhibitor is currently in Phase 1/2 clinical trials, showing favorable safety and tolerability. Concurrently, TuHURA secured a $5 million investment from an existing shareholder to support its Phase 3 trial and ADC development. The agreement includes a payment of $2.5 million at signing, with an additional $2.5 million due by July 15, 2024, and a 90-day exclusivity period.
Kintara Therapeutics and TuHURA Biosciences have announced significant corporate and clinical advances. In April 2024, both companies entered a merger agreement where TuHURA will become a wholly-owned subsidiary of Kintara, expected to close in Q3 2024. Kintara's existing stockholders will own roughly 5.5% of the combined company's stock, including a contingent value right linked to the REM-001 study milestones.
TuHURA is set to advance a Phase 3 trial for its IFx-2.0 personalized cancer vaccine in the second half of 2024. Moreover, TuHURA's ADCs offer potential partnering opportunities. A $31 million financing will support the merger, extending financial runway into late 2025. Kintara also received a 180-day Nasdaq compliance extension to December 9, 2024.
On the clinical front, Kintara has advanced its REM-001 study for cutaneous metastatic breast cancer, having dosed four patients as of June 26, 2024. The study is supported by a $2 million NIH grant. Near-term milestones include closing the merger in Q3 2024 and commencing TuHURA's Phase 3 trial in 2H 2024.
TuHURA Biosciences and Kintara Therapeutics have announced positive results from a Phase 1b trial of their personalized cancer vaccine, IFx-2.0. The trial targeted patients with advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) who were resistant to immune checkpoint inhibitors (ICIs). The vaccine was well-tolerated and showed promising efficacy, with 80% of ICI-naïve patients achieving a durable response.
Data from the study were presented at the 2024 ASCO Annual Meeting. The trial's success has led to the planning of a Phase 3 trial, expected to start in the second half of 2024, using IFx-2.0 in combination with Keytruda to improve tumor response rates.
Additionally, TuHURA has entered into an all-stock transaction with Kintara and secured a $31 million financing to advance their oncology pipeline. The combined company will focus on personalized cancer vaccines and bi-functional Antibody Drug Conjugates (ADCs), operating under the name TuHURA Biosciences and trading on Nasdaq under the ticker HURA.
Kintara Therapeutics (Nasdaq: KTRA) announced its fiscal Q3 2024 financial results ending March 31, 2024. Key developments include a definitive merger agreement with TuHURA Biosciences. Post-merger, Kintara stockholders will own 2.85% to 5.45% of the combined company. The merger is expected to close in Q3 2024. Kintara expanded the inclusion criteria for its REM-001 study and initiated a study in CMBC patients, funded by a $2M NIH grant. Financially, Kintara saw a net loss of $2M ($0.05/share) compared to $3.3M ($1.94/share) in Q3 2023, attributed to lower R&D costs. Cash and equivalents were $6.35M, up from $1.54M in June 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.